Literature DB >> 19805380

Human papillomavirus 16 E7 inactivator of retinoblastoma family proteins complements human cytomegalovirus lacking UL97 protein kinase.

Jeremy P Kamil1, Adam J Hume, Igor Jurak, Karl Münger, Robert F Kalejta, Donald M Coen.   

Abstract

Several different families of DNA viruses encode proteins that inactivate the cellular retinoblastoma tumor suppressor protein (pRb), which normally functions to bind E2F transcription factors and restrict expression of genes necessary for cellular processes including DNA replication. Human cytomegalovirus (HCMV) UL97, a protein kinase functionally orthologous to cellular cyclin-dependent kinases, phosphorylates pRb on inactivating residues during HCMV infection. To assess if such phosphorylation is biologically relevant, we tested whether the human papillomavirus type 16 E7 protein, which inactivates pRb family proteins by direct binding and destabilization, could substitute for UL97 during HCMV infection. In the absence of UL97, expression of wild-type E7 protein, but not a mutant E7 unable to bind pRb family proteins, restored E2F-responsive cellular gene expression, late viral gene expression, and viral DNA synthesis to levels normally observed during wild-type virus infection of quiescent cells. UL97-null mutants exhibited more pronounced defects in virus production and DNA synthesis in quiescent cells as compared to serum-fed, cycling cells. E7 expression substantially enhanced infectious virus production in quiescent cells, but did not complement the defects observed during UL97-null virus infection of cycling cells. Thus, a primary role of UL97 is to inactivate pRb family proteins during infection of quiescent cells, and this inactivation likely abets virus replication by induction of cellular E2F-responsive genes. Our findings have implications for human cytomegalovirus disease and for drugs that target UL97.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19805380      PMCID: PMC2757844          DOI: 10.1073/pnas.0901521106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  57 in total

1.  Structure-function analysis of the human papillomavirus type 16 E7 oncoprotein.

Authors:  W C Phelps; K Münger; C L Yee; J A Barnes; P M Howley
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

Review 2.  Viruses and apoptosis.

Authors:  V O'Brien
Journal:  J Gen Virol       Date:  1998-08       Impact factor: 3.891

3.  p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest.

Authors:  K Polyak; J Y Kato; M J Solomon; C J Sherr; J Massague; J M Roberts; A Koff
Journal:  Genes Dev       Date:  1994-01       Impact factor: 11.361

4.  Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein.

Authors:  D L Jones; K Münger
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

5.  Human cytomegalovirus inhibits cellular DNA synthesis and arrests productively infected cells in late G1.

Authors:  W A Bresnahan; I Boldogh; E A Thompson; T Albrecht
Journal:  Virology       Date:  1996-10-01       Impact factor: 3.616

6.  Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest.

Authors:  F M Jault; J M Jault; F Ruchti; E A Fortunato; C Clark; J Corbeil; D D Richman; D H Spector
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.

Authors:  I Reynisdóttir; K Polyak; A Iavarone; J Massagué
Journal:  Genes Dev       Date:  1995-08-01       Impact factor: 11.361

8.  E2F mediates dihydrofolate reductase promoter activation and multiprotein complex formation in human cytomegalovirus infection.

Authors:  M Wade; T F Kowalik; M Mudryj; E S Huang; J C Azizkhan
Journal:  Mol Cell Biol       Date:  1992-10       Impact factor: 4.272

9.  Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding.

Authors:  Jacob P Lalezari; Judith A Aberg; Laurene H Wang; Mary Beth Wire; Richard Miner; Wendy Snowden; Christine L Talarico; Shuching Shaw; Mark A Jacobson; W Lawrence Drew
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

10.  The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress.

Authors:  Paula M Krosky; Moon-Chang Baek; Donald M Coen
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  29 in total

1.  A viral regulator of glycoprotein complexes contributes to human cytomegalovirus cell tropism.

Authors:  Gang Li; Christopher C Nguyen; Brent J Ryckman; William J Britt; Jeremy P Kamil
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-23       Impact factor: 11.205

Review 2.  Congenital cytomegalovirus infection: molecular mechanisms mediating viral pathogenesis.

Authors:  Mark R Schleiss
Journal:  Infect Disord Drug Targets       Date:  2011-10

3.  A mutation deleting sequences encoding the amino terminus of human cytomegalovirus UL84 impairs interaction with UL44 and capsid localization.

Authors:  Blair L Strang; Brian J Bender; Mayuri Sharma; Jean M Pesola; Rebecca L Sanders; Deborah H Spector; Donald M Coen
Journal:  J Virol       Date:  2012-08-01       Impact factor: 5.103

Review 4.  More than just oncogenes: mechanisms of tumorigenesis by human viruses.

Authors:  Marta M Gaglia; Karl Munger
Journal:  Curr Opin Virol       Date:  2018-09-27       Impact factor: 7.090

5.  Inactivation of retinoblastoma protein does not overcome the requirement for human cytomegalovirus UL97 in lamina disruption and nuclear egress.

Authors:  Natalia I Reim; Jeremy P Kamil; Depeng Wang; Alison Lin; Mayuri Sharma; Maria Ericsson; Jean M Pesola; David E Golan; Donald M Coen
Journal:  J Virol       Date:  2013-02-20       Impact factor: 5.103

6.  Human cytomegalovirus pUL97 regulates the viral major immediate early promoter by phosphorylation-mediated disruption of histone deacetylase 1 binding.

Authors:  Tarin M Bigley; Justin M Reitsma; Shama P Mirza; Scott S Terhune
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

7.  Human cytomegalovirus protein pUL117 targets the mini-chromosome maintenance complex and suppresses cellular DNA synthesis.

Authors:  Zhikang Qian; Van Leung-Pineda; Baoqin Xuan; Helen Piwnica-Worms; Dong Yu
Journal:  PLoS Pathog       Date:  2010-03-19       Impact factor: 6.823

8.  Cyclin-dependent kinase-like function is shared by the beta- and gamma- subset of the conserved herpesvirus protein kinases.

Authors:  Chad V Kuny; Karen Chinchilla; Michael R Culbertson; Robert F Kalejta
Journal:  PLoS Pathog       Date:  2010-09-09       Impact factor: 6.823

9.  Human Cytomegalovirus Can Procure Deoxyribonucleotides for Viral DNA Replication in the Absence of Retinoblastoma Protein Phosphorylation.

Authors:  Chad V Kuny; Robert F Kalejta
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

10.  Comparison of effects of inhibitors of viral and cellular protein kinases on human cytomegalovirus disruption of nuclear lamina and nuclear egress.

Authors:  Mayuri Sharma; Donald M Coen
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.